로딩 중…
지수 로딩 중…
MYUNGIN PHARM.CO., LTD
317450· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩40,000-0.25%
2026-11-02
Financials
Valuation Metrics
MYUNGIN PHARM.CO., LTD's Market Cap is ₩5840B. Ranked #400 of 2,405 in KR market (top 17%), #264 of 778 on KOSPI (top 34%), #43 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 584.00B KRW | KR#400/2,405 Sec#43/231 |
| Revenue | 287.25B KRW | KR#847/2,405 Sec#39/231 |
| Net Income | 81.44B KRW | KR#290/2,405 Sec#19/231 |
| Total Assets | 841.67B KRW | KR#534/2,405 Sec#29/231 |
| Net Assets | 794.38B KRW | KR#350/2,405 Sec#22/231 |
| Value | ||
| P/E | 7.17x | KR#642/2,405 Sec#29/231 |
| P/B | 0.74x | KR#1,238/2,405 Sec#73/231 |
| P/S | 2.03x | KR#1,860/2,405 Sec#108/231 |
| EV/EBITDA | 5.97x | KR#341/2,405 Sec#9/231 |
| FCF Yield | 8.82% | KR#689/2,405 Sec#33/231 |
| Profitability | ||
| ROE | 10.25% | KR#591/2,405 Sec#41/231 |
| ROA | 9.68% | KR#291/2,405 Sec#23/231 |
| Op. Margin | 32.20% | KR#48/2,405 Sec#11/231 |
| Financial Health | ||
| Debt Ratio | 5.95% | KR#47/2,405 Sec#14/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | 51.52B KRW | KR#286/2,405 Sec#16/231 |
| Cash | 31.79B KRW | KR#978/2,405 Sec#66/231 |
| Current Ratio | 13.93x | KR#56/2,405 Sec#17/231 |
| Net Debt/EBITDA | -0.34x | KR#536/2,405 Sec#31/231 |
| Dividend | ||
| Div. Yield | 3.75% | KR#530/2,405 Sec#23/231 |
| Performance | ||
| 1Y Return | -51.34% | KR#1,895/2,405 Sec#161/231 |
| 1M Return | -8.36% | KR#1,018/2,405 Sec#96/231 |
| From 52W High | -57.31% | KR#1,527/2,405 Sec#125/231 |
| 1Y MDD | -56.37% | KR#1,231/2,405 Sec#101/231 |
| Trading | ||
| Volume | 4,678 shares | KR#2,118/2,405 Sec#215/231 |
| Trading Value | 186.2M KRW | KR#1,160/2,405 Sec#133/231 |
| Foreign Own. | 0.89% | KR#2,062/2,405 Sec#203/231 |
| Per Share | ||
| EPS | 5,578 KRW | KR#196/2,405 Sec#10/231 |
| BPS | 54,409 KRW | KR#245/2,405 Sec#14/231 |
Company Info
동사는 1985년 설립되어 유가증권시장에 상장한 중추신경계 치료 약물 전문기업임. 치매, 파킨슨, 뇌전증 등 신경계 약물과 조현병, 우울증, 불안 및 수면치료제 시장에서 국내 1위를 차지하고 있음. 일반의약품 이가탄F와 메이킨Q는 높은 인지도로 시장 선점 중이며, 원료합성부터 완제 의약품 생산까지 전 공정 기술력과 cGMP 기준 생산설비를 보유, 글로벌 제약사와 협력하고 있음. 명인제약는 1988년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.